What are CD47 inhibitor drugs?

CD47 inhibitor drugs are pharmacologic agents that share a common mechanism (typically targeting CD47). 0 are currently marketed, with 5 more in clinical development.

CD47 inhibitor

0 marketed 2 in Phase 3 3 in Phase 2

This page covers all CD47 inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting CD47.

Targets

CD47

Phase 3 pipeline (2)

MB-102 OMID · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Oncology
MB-102 OMID is a monoclonal antibody targeting CD47.
Open single period A140 · Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Oncology
A140 is a monoclonal antibody targeting CD47.

Phase 2 pipeline (3)

ADX415 · Addrenex Pharmaceuticals, Inc. · Oncology
ADX415 is a monoclonal antibody targeting CD47.
ADX-914 · Q32 Bio Inc. · Oncology
ADX-914 is a monoclonal antibody targeting CD47.
CC-97540 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Oncology
CC-97540 is a monoclonal antibody targeting CD47.